发明申请
US20120195851A1 MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY
失效
改良的可溶性FGF受体FC融合，具有改善的生物活性
- 专利标题： MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY
- 专利标题（中）： 改良的可溶性FGF受体FC融合，具有改善的生物活性
-
申请号： US13348297申请日： 2012-01-11
-
公开(公告)号： US20120195851A1公开(公告)日： 2012-08-02
- 发明人: Francis BLANCHE , Beatrice CAMERON , Mark NESBIT , Sylvie SORDELLO , Celine NICOLAZZI , Marc TROMBE
- 申请人： Francis BLANCHE , Beatrice CAMERON , Mark NESBIT , Sylvie SORDELLO , Celine NICOLAZZI , Marc TROMBE
- 申请人地址： FR Paris
- 专利权人： AVENTIS PHARMA SA
- 当前专利权人： AVENTIS PHARMA SA
- 当前专利权人地址： FR Paris
- 优先权： EP06291824.8 20061128; EP07290042.6 20070111
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61P35/00 ; A61P35/02 ; A61K38/19
摘要：
The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
公开/授权文献
- US08481487B2 Modified soluble FGF receptor Fc fusions method 公开/授权日：2013-07-09
信息查询
